Lets not react too quickly to market research base
Post# of 11802
The FDA has yet to wade in, currently allowing the main participants, Abbott and Dexcom, unfettered access to a moderately growing market at relatively low accuracy standards. But FDA will, unless their kill industry/kill innovation mind-set has changed (and it hasn't), set standards in typical knee-jerk fashion, that make it impossible for worthy aspirants to meet, leaving the industry in an FDA caused depression. My personal belief is that CGM will finally emerge in 2022 or 2023. Of the many good things that Trump has done, and IMO he has not done enough at the FDA, has been to lower the level of political appointee to the 4th tier in the FDA center, one tier lower than Obama, and two tiers lower than Bush and Clinton. The latest 4th tier Trump appointees come from industry, which raises the question, why would someone from industry want to work for government.
Nonetheless, market research and publications aside, FDA has yet to cause a technology shake-out --- but they will.
Full confession. I left retirement four months ago and now work for an American arm of a Japanese at-home test strip manufacturer and work full time with my team on CGM. We buy the best market research money can buy and don't believe a word of it.